Naremaddepalli S. Sudarshan

Statistics

Publications

Citations

235

H-Index

Active since

2007

Affiliations

Aurigene Discovery Technologies (India)(Current)

Genalyte (United States)

UNC Lineberger Comprehensive Cancer Center

Beckman Research Institute

Columbia University Irving Medical Center

Naremaddepalli S. Sudarshan is an author at Aurigene Discovery Technologies (India) specializing in immunotherapy, cancer immunotherapy, and tumor immunology.

Publications per year

2007–2021

Publications

PD-1 derived CA-170 is an oral immune checkpoint inhibitor that exhibits preclinical anti-tumor efficacy

Pottayil G. Sasikumar, Naremaddepalli S. Sudarshan, Srinivas Adurthi et al. · Communications Biology · 2021 · 149 citations · Full text

Medicine, Oncology, Pharmacology +17

An Efficient Conversion of the Carboxylic Group of<i>N</i>-Fmoc α-Amino Acids/Peptide Acids into<i>N</i>-Formamides Employing Isocyanates as Key Intermediates

Naremaddepalli S. Sudarshan, N. Narendra, Hosahalli P. Hemantha et al. · The Journal of Organic Chemistry · 2007 · 20 citations

Natural Sciences, Biochemistry, Chemistry +16

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Casey R. Ager, Matthew J. Reilley, Courtney Nicholas et al. · Journal for ImmunoTherapy of Cancer · 2016 · 17 citations · Full text

Medicine, Immunology, Oncology +17

Abstract 4861: Oral immune checkpoint antagonists targeting PD-L1/VISTA or PD-L1/Tim3 for cancer therapy

Pottayil G. Sasikumar, Naremaddepalli S. Sudarshan, Nagaraj Gowda et al. · Cancer Research · 2016 · 13 citations

Medicine, Oncology, Pharmacology +17

CLINICAL STUDY OF ACUTE INTESTINAL OBSTRUCTION

K H Gopalakrishna, Naremaddepalli S. Sudarshan · Journal of Evolution of Medical and Dental Sciences · 2016 · 13 citations · Full text

Medicine, Clinical Sciences, Surgery +17

1–5 of 7